April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
RAVE2 Study : Two years treatment follow up with intravitreal ranibizumab (Lucentis®) and verteporfin PDTRF combination therapy at month 2 for neovascular age-related macular degeneration (AMD)
Author Affiliations & Notes
  • Marcel Dominguez
    Centre Retine Tourny, Bordeaux, France
  • Eric Fourmaux
    Centre Retine Tourny, Bordeaux, France
  • Laurence Rosier
    Centre Retine Tourny, Bordeaux, France
  • Laurent Velasque
    Centre Retine Tourny, Bordeaux, France
  • Footnotes
    Commercial Relationships Marcel Dominguez, None; Eric Fourmaux, None; Laurence Rosier, None; Laurent Velasque, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3961. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marcel Dominguez, Eric Fourmaux, Laurence Rosier, Laurent Velasque; RAVE2 Study : Two years treatment follow up with intravitreal ranibizumab (Lucentis®) and verteporfin PDTRF combination therapy at month 2 for neovascular age-related macular degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2014;55(13):3961.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The synergistic effect of a protocol based on intravitreal injection of ranibizumab (3 injections plus prn) associated with Verteporfin PDT administered at reduced fluence (300 mW/cm2, 25J/cm2) on the day of the 2nd ranibizumab injection was presented in ARVO 2012. This paper evaluates the maintenance of the visual acuity benefit two years after the beginning of the protocol and the number of ranibizumab injections required during the second year.

Methods: Single-center observational follow-up study of 40 patients of any race aged ≥50 years newly diagnosed with subfoveal choroidal neovascularization of any type (≤5400 µm) due to AMD.

Results: Of 40 included patients 27 achieved the study at one year and 23 were followed up for two years. Ages ranged from 60 to 89 years. Primary subfoveal CNV were 18.5% predominantly classic (5), 29.6% minimally classic (8) and 51.9% occult with no classic (14) precisely characterized by ICG and Fluorescein angiography. Mean visual acuity was 66.4 ± 9.6 at baseline, 76.2±8.2 at Month 12 and 70.8 µm±11.8 at Month 24. Mean visual gain was 9.8±11.8 at Month 12 (p=0.0002) and 4.4±14.7 at Month 24 (p=0.1313). 7 patients (25.9%) gained 15 letters or more at 1 year and they were still 6 (22.2%) after two years. Only 4 patients (14.8%) lost more than 15 letters at 1 year and 2 others (7.2%) during the next year. Mean Ranibizumab injections was 4.0 ± 1.3 for the first year and 0.9 ± 1.3 for second year (total of 4.9±2.1 on 2 years). Mean retreatment injection between Month 3 and Month 12 was 1.0 ± 1.3 and between Month 3 and Month 24 was 1.9±2.1. 13 patients (48%) underwent no additional injection after initial treatment regimen.

Conclusions: These results show the maintenance of a visual acuity benefit two years after the therapeutic association with an average number of only one ranibizumab injection during the second year of follow up.

Keywords: 412 age-related macular degeneration • 748 vascular endothelial growth factor • 462 clinical (human) or epidemiologic studies: outcomes/complications  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×